<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126112</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-09-03</org_study_id>
    <secondary_id>2009-016661-28</secondary_id>
    <nct_id>NCT01126112</nct_id>
  </id_info>
  <brief_title>Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer</brief_title>
  <acronym>FRAIL</acronym>
  <official_title>Phase II Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of first-line single-agent&#xD;
      panitumumab in frail elderly patients with advanced Wild Type K-RAS colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of first-line single-agent&#xD;
      panitumumab in frail elderly patients with advanced Wild Type K-RAS colorectal cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 6 months</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient-reported outcomes</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of molecular predictive markers for response.</measure>
    <time_frame>May 2010 - March 2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab: 6 mg/Kg Q2W</description>
    <arm_group_label>Panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Inform Consent&#xD;
&#xD;
          -  Age &gt; 70 years.&#xD;
&#xD;
          -  Histologically documented metastatic colorectal cancer not candidate for surgical&#xD;
             resection&#xD;
&#xD;
          -  Wild type K-RAS&#xD;
&#xD;
          -  Measurable disease by RECIST Criteria&#xD;
&#xD;
          -  Intermediate or High-risk group according to the Köhne Prognostic Classification&#xD;
&#xD;
          -  ECOG status &lt; 3&#xD;
&#xD;
          -  Magnesium ≥ institutional lower limit of normal&#xD;
&#xD;
          -  frail elderly patients and or not candidates for chemotherapy:&#xD;
&#xD;
        Frail elderly patients: Presence of one or more of the following criteria:&#xD;
&#xD;
          -  Dependence for one of the basic daily living activities (Katz Index)&#xD;
&#xD;
          -  Three or more comorbid conditions according Charlson scale and dependence for one of&#xD;
             the instrumental activities of daily living (IADL)&#xD;
&#xD;
          -  Presence one or more of the following geriatric syndromes (age &gt; 85 years, fecal or&#xD;
             urinary incontinence in the absence of stress, frequent falls, spontaneous bone&#xD;
             fractures, neglect)&#xD;
&#xD;
        Presence of one or more of the following criteria that make patients not candidates for&#xD;
        chemotherapy:&#xD;
&#xD;
          -  neutrophils &lt; 2000/mm3&#xD;
&#xD;
          -  platelets &lt; 100.000/mm3&#xD;
&#xD;
          -  creatinine clearance &lt; 30 ml/min and bilirubin levels &gt; 1.5 x ULN&#xD;
&#xD;
          -  creatinine clearance &lt; 30 ml/min and AST or ALT levels &gt; 3 x UNL (if liver metastasis&#xD;
             &gt; 5 x ULN)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they have received prior systemic therapy&#xD;
             for the treatment of metastatic colorectal carcinoma or antiEGFR therapy, with the&#xD;
             exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months&#xD;
             prior to enrolment or oxaliplatin at least 12 months prior to enrolment.&#xD;
&#xD;
          -  Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved&#xD;
             proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion&#xD;
&#xD;
          -  Unresolved toxicities from prior systemic therapy that, in the opinion of the&#xD;
             investigator, does not qualify the patient for inclusion&#xD;
&#xD;
          -  Patients cognitively impaired or with severe depression according mini mental state&#xD;
             examination and geriatric depression scale.&#xD;
&#xD;
          -  Patients with central nervous system metastases, or those with significant&#xD;
             cardiovascular disease, will also be excluded.&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial&#xD;
             pneumonitis or pulmonary fibrosis on baseline chest CT scan&#xD;
&#xD;
          -  Treatment for systemic infection within 14 days before initiating study treatment&#xD;
&#xD;
          -  Radiotherapy &lt; 14 days prior to inclusion in the study.&#xD;
&#xD;
          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea&#xD;
             (defined as &gt; 4 loose stools per day)&#xD;
&#xD;
          -  History of any medical condition that may increase the risks associated with study&#xD;
             participation or may interfere with the interpretation of the study results&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,&#xD;
             chronic active hepatitis B infection&#xD;
&#xD;
          -  subject allergic to the ingredients of the study medication or to Staphylococcus&#xD;
             protein A&#xD;
&#xD;
          -  Any co-morbid disease that would increase risk of toxicity&#xD;
&#xD;
          -  Any investigational agent within 30 days before enrolment&#xD;
&#xD;
          -  Must not have had a major surgical procedure within 28 days of enrolment&#xD;
&#xD;
          -  Subject unwilling or unable to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Sastre</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Clínico San Carlos. Madrid. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced colorectal cancer; K-RAS; panitumumab</keyword>
  <keyword>advanced Wild Type K-RAS colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

